Cost-effectiveness of fluticasone propionate/salmeterol (500/50 μg) in the treatment of COPD

Respiratory Medicine

Volumn 103, Issue 1, 2009, Pages 12-21

  Earnshaw, Stephanie R ^a   Wilson, Michele R ^a   Dalal, Anand A ^b   Chambers, Mike G ^b   Jhingran, Priti ^b   Stanford, Richard ^b   Mapel, Douglas W ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

COPD; Cost effectiveness analysis; Economics

Indexed keywords

AMOXICILLIN; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PREDNISONE; SALBUTAMOL; SALMETEROL;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RECURRENCE; RISK; TREATMENT OUTCOME;

EID: 58049090292     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.10.005     Document Type: Article

References (35)

1. Mannino A.M., Heron M.P., Murphy S.L., and Kochanek K.D. Deaths: final data for 2004. National vital statistics reports 53 (2007), National Center for Vital Statistics, Hyattsville, MD
2. National Heart Lung and Blood Institute (NHLBI). Morbidity and Mortality Chartbook; 2004.
3. Celli B.R., MacNee W., and Committee Members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 923-946
4. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
5. Gartlehner G., Hansen R.A., Carson S.S., and Lohr K.N. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 4 3 (2006) 253-262
6. Hanania N.A., and Sharafkhaneh A. Update on the pharmacologic therapy for chronic obstructive pulmonary disease. Clin Chest Med 28 (2007) 589-607
7. Sin D.D., and Tu J.V. Inhaled corticosteroids and their risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 580-584
8. Suissa S. Effectiveness of inhaled corticosteroids in COPD: immortal time bias in observational studies. Am J Respir Crit Care Med 168 (2003) 49-53
9. Kiri V.A., Pride N.B., Soriano J.B., and Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from tow observational designs free of immortal time bias. Am J Respir Crit Care Med 172 (2005) 460-464
10. Mapel D.W., Nelson L.S., Lydick E., Soriano J., Yood M.U., and Davis K.J. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD 4 2 (2007) 127-134
11. Calverley P., Anderson J., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
12. Oostenbrink J.B., Rutten-van Molken M., Monz B.U., and Fitzgerald J.M. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8 1 (2005) 32-46
13. Sin D.D., Golmohammadi K., and Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 116 (2004) 325-331
14. Borg S., Ericsson A., Wedzicha J., Gulsvik A., Lundback B., Donaldson G.C., et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 7 2 (2004) 153-167
15. Spencer M., Briggs A.H., Grossman R.F., and Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23 (2005) 619-637
16. Hoogendoorn M., Rutten-van Molken M.P., Hoogenveen R.T., van Genugten M.L., Buist AS,Wouters E.F., and Feenstra T.L. A dynamic population model of disease progression in COPD. Eur Respir J 26 (2005) 223-233
17. van der Palen J., Monninkhof E., van der Valk P., Sullivan S.D., and Veenstra D.L. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 61 (2006) 29-33
18. American Thoracic Society (ATS)2007. Spirometric classification. http://www.thoracic.org/sections/copd/index.html [accessed 10.12.07]
19. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
20. Stanford R.H., Yingjia S., and McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat Respir Med 5 5 (2006) 343-349
21. Mayers I., Jacobs P., Marciniuk D.D., Chuck A., and Varney J. Long-acting β2-agonists (LABA) plus corticosteroids versus LABA alone for chronic obstructive pulmonary disease. [Technology report no. 83] (2007), Canadian Agency for Drugs and Technologies in Health, Ottawa
22. 1: the lung health study. JAMA 272 (1994) 1497-1505
23. Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jenkins C.R., Jones P.W., et al. Effect of pharmacotherapy on rate of decline in lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178 (2008) 332-338
24. Hoyert D.L., Hsiang-Ching K., and Smith B.L. Deaths: preliminary data for 2003 (2005), United States Department of Health and Human Services, Hyattsville, MD Report no. 32
25. The Essential RBRVS: a comprehensive listing of RBRVS values for CPT and HCPCS codes (2005), Ingenix, Inc., Utah
26. U.S. Department of Labor: Bureau of Labor Statistics. Consumer price index - all urban consumers. [current series]. 13 March 2006. Available from:. http://data.bls.gov/PDQ/outside.jsp?survey=cu
27. ®, Version 61135 vol. 46 (October 2007), Thomson PDR, Montvale, N.J.
28. Paterson C., Langan C.E., McKaig G.A., Anderson P.M., Maclaine G.D.H., Rose L.B., et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQoL (EQ-5D). Qual Life Res 9 (2000) 521-527
29. Spencer S., and Jones P.W. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58 (2003) 589-593
30. Weinstein M.C. From cost-effectiveness ratios to resource allocation: where to draw the line. In: Sloan F.A. (Ed). Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies (1995), Cambridge University Press, New York
31. Eichler H., Kong S.X., Gerth W.C., Mavros P., and Jonnson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 7 5 (2004) 518-528
32. Hirth R.A., Chernew M.E., Miller E., Frederick A.M., and Weissart W.G. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 20 (2000) 332-342
33. Hanania N.A. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther 29 10 (2007) 2121-2133
34. Menzin J., Boulanger L., Marton J., Guadagno L., Dastani H., Dirani R., et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 102 (2008) 1248-1256
35. 1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 131 (2007) 682-689